18 February 2026
18 February 2026
The designation supports priority engagement with the FDA as Portal Diabetes advances clinical trials and regulatory submissions.
The therapy dosing provides clinical outcomes consistent with those of the earlier approved bi-weekly subcutaneous regimen.
The acquisition will combine two portfolios that focus on advancing spine care solutions.
Recruitment is ongoing in China and Australia, with IND clearance now obtained in the US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
